Epigenetic Modulations and Lineage Plasticity in Advanced Prostate Cancer by Ge, R. et al.
Epigenetic Modulations and Lineage Plasticity in Advanced Prostate Cancer 
R. Ge1, Z. Wang2, R. Montironi3, Z. Jiang1, M. Cheng4, M. Santoni5, K. Huang4, F. Massari6, X. 
Lu7,8, A. Cimadamore3, A. Lopez-Beltran9,10, and L. Cheng11,12*
1Department of Pathology, University of Massachusetts Medical Center, Worcester, MA, USA; 
2Department of  Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, 
Boston, MA, USA; 3Section of Pathological Anatomy, Polytechnic University of the Marche 
Region, School of Medicine, United Hospitals, Ancona, Italy; 4Department of Medicine, Indiana 
University School of Medicine, and Regenstrief Institute, Indianapolis, USA; 5Oncology Unit, 
Macerata Hospital, Macerata, Italy; 6Division of Oncology, S. Orsola-Malpighi Hospital, 
Bologna, Italy; 7Harper Cancer Research Institute, 8Department of Biological Sciences, Boler–
Parseghian Center for Rare and Neglected Diseases, University of Notre Dame, Notre Dame, IN, 
USA; 9Department of Pathology and Surgery, Faculty of Medicine, Cordoba University, 
Cordoba, Spain and 10Champalimaud Clinical Center, Lisbon, Portugal; 11Department of 
Pathology and Laboratory Medicine, 12Department of Urology, Indiana University School of 
Medicine, Indianapolis, IN, USA.
Running Head: Epigenetic Modulations and Lineage Plasticity 
Conflict of Interest: None 
Total number of text pages, 29; Number of tables, 2; Number of figures, 2; word count: 4155 
*Address correspondence and reprint requests to Prof. Liang Cheng, Department of Pathology 
and Laboratory Medicine, Indiana University School of Medicine, 350 West 11th Street, IUHPL 




This is the author's manuscript of the article published in final edited form as: 
Ge, R., Wang, Z., Montironi, R., Jiang, Z., Cheng, M., Santoni, M., ... & Lopez-Beltran, A. (2020). Epigenetic Modulations and Lineage Plasticity in 
Advanced Prostate Cancer. Annals of Oncology. https://doi.org/10.1016/j.annonc.2020.02.002
2 
ABSTRACT 
Prostate cancer is the most common cancer and second leading cause of cancer death in 
American men. Anti-androgen therapies are part of the standard of therapeutic regimen for 
advanced or metastatic prostate cancers. However, patients who receive these treatments are 
more likely to develop castration-resistant prostate cancer (CRPC) or neuroendocrine prostate 
cancer (NEPC). In the development of CRPC or NEPC, numerous genetic signaling pathways 
have been under preclinical investigations and in clinical trials. Accumulated evidence shows 
that DNA methylation, chromatin integrity and accessibility for transcriptional regulation still 
play key roles in prostate cancer initiation and progression. Better understanding of how 
epigenetic change regulates the progression of prostate cancer and the interaction between 
epigenetic and genetic modulators driving NEPC may help develop a better risk stratification 
and more effective treatment regimens for prostate cancer patients. 
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Prostate cancer is a frequently detected cancer in the United States for men over 50 years of 
age. Despite recent therapeutic advances, prostate cancer still represents a major urological 
disease associated with substantial morbidity and mortality [1, 2]. Androgen deprivation therapy 
(ADT) has been the cornerstone treatment for advanced and metastatic prostate cancers. Despite 
initial high response rates, cancer management with ADT is of limited duration; nearly all men 
eventually develop progressive prostate cancer following ADT. This is referred to as castration-
resistant prostate cancer (CRPC) [3]. This progression may be caused by a series of mechanisms, 
which include but not limit to AR-dependent mechanisms of resistance [4, 5] and a 
glucocorticoid receptor-adaptive resistance mechanism [6]. CRPC is also conferred by a 
frequently occurring AR splice variant. One of the most common variants is AR variant 7 
(ARv7) [7-8].  
In light of the accumulated evidence for developing resistance mechanisms, epigenetic 
alterations result in enhanced or attenuated transciptional activity and play important roles in 
pro-oncogenic role of AR signaling. This is mediated by either DNA/chromatin methylation, 
histone modification to affect the direct binding of AR to DNA, posttranslational modifications 
in the AR itself or AR-cofactors leading to gain-of-function [9].  
Another increasingly accepted mechanism of resistance is lineage plasticity, which appears 
in multiple cancer types, including prostate cancers [10-12]. Lineage plasticity denotes a process 
by which cancer cells change from one morphological and functional cell type to another, under 
the influence of environmental pressures. In the context of prostate cancer treatment, lineage 
plasticity refers to a shift in cellular phenotype from an AR-dependent adenocarcinoma to an 
AR-indifferent neuroendocrine carcinoma, which likely occurs following ADT. Lineage 
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plasticity has a markedly different epigenetic profile, low AR signaling, and acquired expression 
of neuroendocrine stem cell markers [13]. Given that e appearance of neuroendocrine cells in 
prostate cancer is associated with aggressive tumors and poor prognosis [14], better 
understanding of the genetic and epigenetic mechanisms by which NEPC develops is necessary 
to design therapeutic strategies for NEPC patients.  
 
Epigenetic changes drive the progression of prostate cancer 
Epigenetic controls of transcriptional regulation include DNA methylation, histone 
modification, and chromatin remodeling. These epigenetic modifications drive carcinogenesis in 
prostate cancers [15]. A genomic landscape study of primary and metastatic prostate cancers has 
identified mutations in many epigenetic regulators and chromatin remodelers in up to 20% of 
advanced prostate cancers [11, 15-18]. These mutations are associated with high-grade prostate 
cancer [19] and development of CRPC and NEPC [20].  
 
DNA methylation  
A family of DNA methyltransferases (DNMT) catalyzes the transfer of a methyl group from 
S- adenosylmethionine to the fifth carbon of cytosine residue to form 5-methylcytosine (5mC) 
[21]. DNMT1, one of the major subtypes of DNMT, has tumor suppressor activity in early-stage 
prostate cancers but oncogenic activity in advanced prostate cancers, and metastasis through 
induction of epithelial–mesenchymal transition and cancer stem cell phenotype [22, 23]. 
Aberrant DNA methylation is usually associated with aggressive clinicopathological features and 
poor survival. Interestingly, our recent study suggests that DNMT1 regulates expression of 
steroid 5-α reductase 2 (SRD5A2). SRD5A2 gene methylation in promoter region is associated 
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with better survival for CRPC patients treated with ADT. This is the first study to our best 
knowledge that showing increased methylation level is associated with better prognosis in 
advanced prostate cancers (data in preparation). Further exploring the epigenetics of DNMT and 
SRD5A2 may help us better understand the relationshp between epigenetics and development of 




Although DNA methylation has been known for decades, how DNA demethylation occurs 
remained unclear until the discovery of TET enzymes and the ability to oxidize 5mC to 5hmC 
[24]. TET family proteins promote locus-specific reversal of DNA methylation in normal cells 
which ensures that DNA methylation patterns and gene expression are precisely regulated [25]. 
TET-mediated 5hmc level in genomic DNA is usually decreased in many types of solid tumors, 
including prostate cancers [26, 27]. In prostate cancers, the tumor-suppressive TET family 
proteins, which are involved in DNA demethylation, are repressed; in particular, TET2 is 
involved in the AR signaling and has an important role in prostate cancer development. For 
example, Takayama et al [28] reported that the AR-induced miR-29 family specifically 
downregulates TET2 in prostate cancers, resulting in activation of AR and mTOR signaling and 
reduced expression of both TET2 and 5hmC which are associated with prostate cancer 
progression. In a similar study, TET proteins were found to suppress tumor progression and 
invasion partly through downregulation of critical gene methylation [29]. Storebjerg et al [30]  
reported that TET family proteins and the epigenetic mark 5hmC have been found to be a novel 
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candidate prognostic biomarker. Further studies are w rranted to explore the epigenetic 
mechanisms of TET proteins in CRPC and NEPC. 
 
Histone modifications 
The role of histone modifications has been recognized n prostate cancer for a long time. For 
instance, WHSC1 (also known as NSD2), the histone dim thyl methyltransferase was found to 
be stabilized by AKT and its stabilization plays a causal role in driving prostate cancer 
metastasis [29]. Aytes et al [31] demonstrated that NSD2 is a robust marker of lethal metastatic 
prostate cancer and a potential biomarker for prostate cancer diagnosis. Study also found that 
another histone demethylase JMJD1A functions as a key coactivator for AR by epigenetic 
regulation of H3K9 methylation. JMJD1A recruits HNRPF to promote alternative splicing of 
AR-V7 in prostate cancer cells, and silencing of JMJD1A reduced the level of AR-V7 in prostate 
cancer cells [32]. JMJD2A, another subtype of histone demethylase has also been found to drive 
prostate carcinogenesis through transcription factor ETV1 [33]. In addition, histone 
acetyltransferase Bromodomain-containing proteins, particularly BRD4  has been found to bind 
to acetylated lysine on histones and play an important role in prostate cancer progression [34].  
A recent study further reported a novel chromatin-regulated mechanism of AR transcriptional 
regulation being mediated by the tyrosine kinase ACK1 (also known as TNK2) [35]. 
ACK1/TNK2 phosphorylates histone H4 at Try88 upstream of the AR transcription start site, 
leading to WDR5/MLL2 complex-mediated increase of AR transcription and the epigenetic 
regulatory circuits drive CRPC progression. Reversal of the pTry88-histone H4 epigenetic marks 
by the ACK1 inhibitor (R)-9bMS sensitizes naive and ADT-resistant prostate cancer cells and 
reduces AR expression and halts CRPC growth [35]. 
7 
 
LSD1 (also known as KDM1A), a FAD-dependent demethylase, functions as a 
transcriptional repressor of AR-regulated enhancers through H3K4 and H3K9 demethylation and 
as an AR coactivator through interaction with RCOR1/CoREST and phosphorylation of histone 
H3 Thr-6 (H3T6ph) [36]. LSD1 was found to promote CRPC also through epigenetic 
programming to induce CENPE, a centromere binding protein and mitotic kinesin, expression 
[37].  LSD1 is significantly upregulated in CRPC, which may suggest serve as a predictive 
biomarker of aggressive prostate cancer. Targeting LSD1 in conjunction with AR antagonists 
may also be a promising therapeutic approach to treat CRPC [38]. LSD1 inhibitors are under 
clinical investigation for prostate cancer and other cancers [39].  
 
Repressor Element 1-Silencing Transcription factor (REST) 
REST is an important epigenetic regulator which is often dysregulated in NEPC [40]. REST 
is widely expressed in embryonic stem cells, where it orchestrates a set of epigenetic 
modifications, thus mediating the plasticity of gene chromatin by recruiting co-repressors, such 
as EZH2 and LSD1, to repress neuronal differentiation. The linkage between epigenetic 
mechanisms and neurogenesis has been documented by REST [41]. In prostate cancers, REST 
mediates AR repression and is a key mediator of neuroendocrine transdifferentiation mediated by 
androgen depletion [42]. REST reduction plays an important role in hypoxia-mediated 
neuroendocrine differentiation of prostate cancers through activation of AMPK/mTOR pathway 
[43]. 
 
Polycomb group proteins 
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The polycomb group proteins are other epigenetic modulators with strong links to cellular 
dedifferentiation and malignant progression. Polycomb group proteins consist of two main 
repressive complexes, PRC1 and PRC2. PRC2 binds to H3K27me3 and represses neighboring 
nucleosomes. The methylation requires physical interac ion between EZH2 and EED, the two 
core catalytic subunits of PRC2 [44, 45]. In the context of prostate cancers, EZH2 
overexpression is associated with cancer progression [46] and can be inhibited by microRNA-
101 [47]. Clermont et al [48] established the in vivo model of ADT-induced NEPC using patient-
derived xenografts and also showed that EZH2 and CBX2, a PRC2 component, are the most 
highly expressed epigenetic regulators in the NEPC tumor model compared with the original 
prostate adenocarcinoma (PADC). Other studies also demonstrated that upregulation of EZH2 is 
a well-established driver of NEPC progression [11, 17, 49, 50].In the MYCN-driven NEPC 
mouse model, EZH2 functions directly with MYCN to suppress the AR signaling which 
promotes NEPC development [51]. Although the precise role of EZH2 in the emergence and 
maintenance of the NEPC phenotype remains unclear, EZH2 has been identified as an important 
target with promising therapeutic effects [51]. In addition, BMI1, the component of PRC1, was 
reported to be upregulated in prostate cancers. BMI1 ubiquitylates histone H2A through its 
catalytic subunits RING1A or RING1B [52] and plays an important role in epigenetic regulation 
of cell differentiation and cancer stem cell self-rnewal [53].  
In one word, aberrant epigenetic modifications are crucial for prostate cancer progression. 
Recent whole-genome bisulfite sequencing coupled with transcriptome data revealed that 
multiple genetic pathways are also epigenetically dysregulated in NEPC including those 
involved in cell–cell adhesion, development of epithelial–mesenchymal transition, and the 
9 
 
regulation and maintenance of stem cells [11]. Investigating the interaction between epigenetic 
and genetic regulators might be an innovating research field for the advanced prostate cancer.  
 
Lineage plasticity driving development of NEPC 
Clinical and genomic profiling suggest that NEPC may originate de novo from a scattered 
neuroendocrine cells (usually less than 1% of total cell population) in PADC [54]. CXCL8 (also 
known as IL-8), chemokine receptor CXCR2, and CXCL8–CXCR2–TP53 signaling keep the 
neuroendocrine cells in adenocarcinoma in a quiescent state. A TP53 mutation in the 
neuroendocrine cells can destroy the balance and led to rapid progression of NEPC from PADC 
[55]. However, in the majority of cases, NEPC-like cells may develop from a population of 
luminal-epithelial cells following ADT [56]. Recent developed next-generation sequencing 
(NGS) has made it possible to sequence prostate cancer of different stages, from PADC to NEPC 
[10, 57, 58], and identify different genetic mechanisms underlying lineage plasticity or PADC-
to-NEPC transdifferentiation. For example, NGS verifi d that NEPC not only has mutation or 
loss of TP53, but is also enriched for loss of RB, loss of AR and AR target gene expression, and 
overexpression of MYCN (chromosome 2p24, encoding N-MYC) and AURKA (encoding 
Aurora-A) [11, 17, 59]. Other studies also suggested that neuroendocrine transdifferentiation of 
PADCs are driven by variable genetic mechanisms such as overexpression of SRRM4 [60], 
hypoxia-mediated signaling [43, 61], PKC-lambda/iota reduction [62], and elevated HP1α 
expression [63]. In addition, tumor-associated macrophages (TAM) are an important component 
of tumor microenvironment. Recently, Zarif et al [64] showed that TAM can reprogram tumor 
phenotype and play a major role in the emergence of a neuroendocrine phenotype in prostate 
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cancers. Targeting these signals in the prostate cancer microenvironment could potentially 
augment immunotherapeutic approaches in NEPC. 
  
Crosstalk between genetic and epigenetic modulators in NEPC progression 
Loss of RB1 and TP53 
Cooperative loss of RB1 and TP53 was present in 53.3% of NEPC vs 13.7% of PADC [11]. 
One study also reported that combined loss of RB1 and TP53 in the anti-androgen–sensitive 
LNCaP-AR prostate cancer cell line facilitated acquisition of ADT resistance and led to 
increased lineage plasticity. However, this resistance and phenotypic shifting to NEPC could be 
reversed by re-expressing RB1 and TP53 proteins [49]. Ku et al [65] reported a similar finding as 
RB1 loss facilitated phenotypical shifting from luminal cells to neuroendocrine-like cells and 
metastasis of PADC initiated by PTEN mutation. The additional loss of TP53 in this model 
accelerated the onset of expression of neuroendocrine markers and anti-androgen resistance. In 
addition, they also demonstrated that RB1 and TP53 loss in prostate cancers upregulated 
epigenetic-important reprogramming factors EZH2 andSOX2; thus creating a stem cell–like 
epigenetic environment permissive for lineage plasticity. The repression of EZH2 or SOX2 by 
epigenetic modulation (such as histone H3K27 methyla ion inhibitor) reversed or delayed the 
lineage switch and restored sensitivity to ADT [49, 65]. SOX2 is one of four transcriptional 
factors (OCT4, SOX2, LIN28, and NANOG) involved in regulating self-renewal and 
reprogramming fibroblasts to induced pluripotent stem cells [66]. These factors were reported to 
be sufficient to reprogram somatic cells into induced pluripotent stem cells, promoting lineage 
plasticity in prostate cancer following ADT [49]. Therefore, loss of TP53 and RB1-mediated 
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lineage plasticity is closely cooperative with epigenetic mechanisms in driving NEPC 
development. 
 
MYCN and AURKA amplification 
Concurrent MYCN (encoding N-MYC) and AURKA (encoding Aurora-A) gene 
amplification are more significant events in NEPC, compared with PADC [17, 51]. Forty percent 
of NEPC overexpressed both genes, compared with 5% of PADCs. N-MYC is critical for 
maintenance of human embryonic stem cells as well as neural stem and precursor cells [67, 68]. 
It is well demonstrated that N-MYC drives NEPC from human prostate epithelium [17, 51]. Lee 
et al [22] also reported that N-MYC and activated AKT1 are sufficient to transform human 
prostate epithelial cells to PADCs and NEPCs. Although direct pharmacological inhibition of N-
MYC has proven challenging, N-MYC can be stabilized by N-MYC/Aurora-A dimerization. 
This complex is targetable by Aurora-A inhibitors [22, 69, 70]. Aurora-A inhibitors, such as 
alisertib [71] and CD532 [70], have demonstrated significant anti-tumor activity associated with 
a significant reduction in MYCN protein levels [51]. A clinical trial also reported that some 
advanced prostate cancer patients with Aurora-A and N-MYC activation achieve significant 
clinical benefit from alisertib [72].   
Moreover, Berger et al [73] uncovered a potential mechanism by which overexpressed N-
MYC interacts with AR cofactors (such as FOXA1 and HOXB13). These cofactors may alter 
MYCN DNA binding through competition at N-MYC binding sites or by altering the chromatin 
accessibility. The authors also described that epigenetic bivalent markers 
(H3K4me3/H3K27me3) and EZH2 activity specifically associated with lineage-defining genes 
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were reprogrammed by N-MYC. Finally, they demonstrated that N-MYC–induced gene 
expression and epigenetic changes may accurately classify the patient cohort.  
 
Overexpression of SRRM4 
SRRM4 is a master regulator required for neural differentiation from embryonic stem cells 
[74]. Some SRRM4-targeted genes, such as REST and PHF21A, in neural cells have been 
identified in NEPC, suggesting that SRRM4 is functionally active in NEPC and might drive 
neuroendocrine transdifferentiation of PADCs [60]. Consistent with these findings, data obtained 
from clinical prostate cancer cohorts confirmed that SRRM4 is highly expressed in 50% of 
NEPCs versus 3% of PADCs [75]. Li and colleagues [60] performed whole transcriptome 
analyses on patient samples [17, 40] and determined that SRRM4 is an upstream regulator of 
REST, an epigenetic regulator, and regulates REST splicing in prostate cancers. They also 
demonstrated that SRRM4 is a powerful driver of NEPC transdifferentiation [60]. In other 
studies, SRRM4 stimulated adenocarcinoma cells to express NEPC biomarkers, which was 
exacerbated by ADT [76]. SRRM4-mediated development of NEPC under ADT was further 
augmented with the loss of TP53 and RB1 [60]. SRRM4 may also induce the expression of key 
reprogramming factors, such as SOX2, to promote lineage plasticity, thus driving NECP 
development [77]. However, the mechanisms of induction of SRRM4 remain unclear. No NEPC-
specific mutations were found in the SRRM4 promoter; therefore, induction of SRRM4 gene 
expression could be controlled by epigenetic mechanisms. One study identified that several 
SRRM4 target genes are histone acetyltransferases or de-methyltransferases (e.g., MEAF6 and 
BHC80) and may promote NEPC progression through epigenetic mechanism [78]. Therefore, 
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crosstalk between epigenetics and gene expression of SRRM4 warrants further investigations. 
Nevertheless, these findings may guide the development of novel therapeutics aimed at NEPC. 
 
FOXA1 loss and FOXA2 gain 
The FOXA family proteins, particularly FOXA1 and FOXA2, are implicated in the 
development of NEPC. Studies showed that FOXA1 is transiently upregulated in localized 
prostate cancer but downregulated in CRPC [79, 80] and further downregulated in NEPC [81]. 
FOXA1 loss upregulates CXCL8 in NEPC [82] and CXCL8-activated MAPK/ERK 
phosphorylation promote neuroendocrine differentiation of prostate cancer cells. Moreover, 
FOXA1 has been also reported to play pioneering and reprogramming roles in lineage 
conversion [83]. Genome-wide location analyses show that FOXA1 physically interacts with 
TET1 proteins, a 5-methylcytosine dioxygenase. TET1 can potentiate FOXA1 recruitment 
through regulating local DNA demethylation and concomitant histone H3 lysine 4 methylation 
and FOXA1 binding can be reduced following TET1 depletion [84]. This study unraveled the 
potential crosstalk mechanism between FOXA1 signaling and epigenetics and further explained 
the molecular mechanisms of how FOXA1 drives prostate c ncer progression through epigenetic 
modifications. On the other hand, overexpression of FOXA2 was reported in a genetically 
engineered mouse model of NEPC [85] and the N-MYC/AKT1–driven NEPC [22]. Assessment 
of FOXA2 expression in clinical prostate cancer specim ns interestingly showed that FOXA2 
expression is not detectable in PADCs, whereas it is highly expressed in NEPCs [86]. HIF1α is a 
hypoxia-induced gene and interacts with REST[43] and lso partners with FOXA2 to promote 
prostate cancer development[87]. Therefore, whether FOXA2 could induce phenotypical 
switching from PADC to NEPC via the HIF1A-REST–mediated epigenetic mechanism requires 
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further investigation. Nevertheless, given the important regulatory roles of FOXA1/FOXA2 in 
NEPC progression, and their close relationship withepigenetic mediators, a better understanding 
of crosstalk between FOXA family proteins and epigenetic modulators in NEPC could discover a 
possible new therapeutic strategy.  
 
Hypoxia mediated neuroendocrine differentiation 
Hypoxia is an evident in prostate cancer development, increasing with clinical stage, patient 
age [88]. Recently, Guo et al [61] reported that hypoxia promotes neuroendocrine 
transdifferentiation in PADCs through ONECUT2 signali g. ONECUT2 is found to regulate 
hypoxia-induced gene expression in NEPCs and activate SMAD3, a cofactor of HIF1A. In 
another study, it was reported that ONECUT2 also suppresses the translational activity of AR 
and represses the expression of FOXA1 through regulating PEG10, thus driving NEPC. The 
authors also showed that treatment with a small molecule inhibitor, CSRM617, against 
ONECUT2 has promising effects in prostate cancers [89]. Kim et al [90] reported that PEG10 is 
highly expressed in NEPC. Targeting PEG10 reduces proliferation rate and expression of 
neuroendocrine markers. It has been known for years th t PEG10 is a paternally expressed 
imprinted gene. Similar to other imprinted genes, PEG10 expression is closely regulated by 
epigenetics [91]. Moreover, in the context of advanced prostate cancers, whether hypoxia drives 
NEPC development through PEG10 mediated epigenetics r mains unknown. In other studies, 
Lee et al [92] reported that histone demethylase KDM3A served as a transcriptional coactivator 
of HIF1A in regulation of their target genes in prostate cancer. In a similar study, KDM3A was 
reported to be positively regulated by PHF8, indirectly sustaining H3K4me3 levels on select 
hypoxia-inducible genes in prostate cancers [93]. As mentioned above, Lin et al also reported 
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that REST is involved in hypoxia-mediated neuroendocrine differentiation of prostate cancers 
[43]. Altogether, these studies indicate that epigenetic signatures may be one of important 
mechanisms involved in hypoxia-induced NEPC progression.  
 
PKC-lambda/iota reduction 
In a recent study, Reina-Campos et al [62] analyzed clinical metastatic NEPC samples and 
identified that PKC-lambda/iota is reduced in NEPC during ADT, which lead to 
mTORC1/ATF4-driven upregulation of serine synthesis. Serine is the major source of one-
carbon units for methylation reactions that occur via the generation of S-adenosylmethionine 
[94]. In this study, serine is found to facilitate tumor growth and to epigenetically switch to the 
NEPC phenotype. Interestingly, when the PKC-lambda/iota deficiency cells were treated with 
decitabine or cycloleucine, which competitively inhibits the enzyme methionine 
adenosyltransferase resulting in the inhibition of S-adenosylmethionine synthesis reducing 
methyl donor supplies for the DNMT reaction, both trea ments significantly reduced the 
expression of basal and NEPC biomarkers and had potent antiproliferative effects on PKC-
lambda/iota deficiency cells. Because serine is a nonessential amino acid, treatments targeted at 
blocking serine synthesis will only impact prostate cancer, without toxic side effects to benign 
tissues [62]. 
 
Elevated HP1α expression 
Ci et al [63] recently identified 36 heterochromatin-related genes by analysis of patient-
derived xenograft, multiple patient cohorts, and genetically engineered mouse models. They 
showed that NEPC have a distinctive heterochromatin gene signature compared with PADCs. 
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Within this gene signature, elevated HP1α expression is an early event in NEPC development 
and is associated with a poor prognosis. They also showed that HP1α promotes neuroendocrine 
transdifferentiation of PADCs following ADT. Silenci g of HP1α reactivates AR and REST 
expression and inhibits NEPC tumor growth [63]. The c romodomain of the HP1 proteins 
recognizes H3K9me3 and this interaction forms the basis for further recruiting of other 
heterochromatin-associated proteins, thereby initiating chromatin modification and gene 
silencing [95]. Interestingly, DEK1, an epigenetic regulator, was reported to interact directly 
with HP1α and significantly enhance its binding to trimethylated H3K9 (H3K9me3). The DEK1-
mediated epigenetic event has been identified as an important role in driving NEPC [96]. 
Altogether, these studies suggest that an HP1α-dependent mechanism is a potential functional 
driver promoting NEPC development via regulating specific epigenetic mechanism.  
 
Silencing of RASAL3 and glutamine secretion in tumor microenvironment 
It has been long known that cancer-associate fibroblasts can promote the progression and/or 
initiation of prostate epithelial cells via regulating extracellular matrix and growth factors [97]. 
Mishra et al [98] also reported that epigenetic changes in prostatic cancer–associated fibroblasts 
initiate stromal–epithelial interactions. This interaction facilitated tumor growth and 
development of resistance to ADT. Analysis of DNA methylome revealed that epigenetic 
silencing of RASAL3, a Ras inhibitor, in prostatic cancer–associate fibroblasts activated Ras 
signaling, thus driving macropinocytosis-mediated glutamine synthesis. Glutamine uptake by 
prostate cancer epithelia promotes tumor neuroendocrine differentiation indicating the Ras-
mediated metabolic reprogramming in prostatic cancer–associate fibroblasts driving NEPC. The 
RASAL3 epigenetic silencing and glutamine secretion by prostatic fibroblasts can be further 
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enhanced following ADT. The authors also suggested that therapeutic strategies to prevent 
glutamine uptake be considered in conjunction with ADT.  
Altogether, lineage plasticity has been an important mechanism driving neuroendocrine 
transdifferentiation in PADCs. Different genetic signaling pathways and tumor 
microenvironments could be involved in the plasticity mechanism. However, many of the 
components in driving lineage plasticity have been found to have a bridge with epigenetic 
modulators (Figure 1). Therefore, a better understanding of how the intrplay between 
epigenetics and plasticity mechanisms helps us to gain insights into the advanced prostate cancer 
progression and develop effective therapeutic approaches for advanced prostate cancer patients.  
 
Potential therapeutic options for NEPC 
Targeting epigenetic effectors will have clinical benefits for prostate cancer patients.  BET 
bromodomain inhibitors, histone methyltransferase inhibitors, DNMT inhibitors, HDAC 
inhibitors, and many other numerous epigenetics therapi s (Figure 2) are currently in clinical 
trials. Active and completed clinical trials involving epigenetic drugs are summarized in Table 
1.  
Not only have drugs targeting epigenetic modulators been developed, but other regimen-
targeting genetic modulators are under preclinical and clinical investigations (Table 2). For 
example, alisertib/MLN8237 inhibits the interaction between N-MYC and its stabilizing factor 
Aurora-A, thus inhibiting N-MYC signaling and delaying NEPC growth [72]. Rovalpituzumab 
tesirine, a DLL3-targeted antibody-drug conjugate in NEPC is also under clinical trial. A single 
therapeutic agent is often not enough for treatment of advanced prostate cancers. Therefore, 
combined therapeutic agents, such as olaparib combined with cabazitaxel, carboplatin, and 
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prednisone, and Radium-223 combined with dexamethasone in aggressive prostate cancers, are 
also in clinical trials. Antabuse (disulfiram) administration of intravenous copper chloride in 
combination with oral disulfiram in CRPC and NEPC are lso under clinical investigation. This 
therapeutic combination acts by activating reactive oxygen species (ROS) and inhibiting DNMT 
and ubiquitin/proteasomal signaling [99, 100]. Platinum-based therapy in combination with 
docetaxel is also a common treatment option for NEPC [101-102]. 
However, development of epigenetic therapy is stillchallenging. One of major obstacles is 
that most epigenetic therapies have nonspecific distributions and exert their functions over an 
extensive transcriptional network and are not able to achieve cancer cell specificity, leading to 
undesirable off-target and toxic side effects [103-5]. As our understanding of the epigenetic 
alterations in human prostate cancers becomes more advanced, the field will have many 
opportunities to translate this into impactful clinical management of prostate cancers, especially 
CRPC and NEPC. Among the different classes of epigenetic alterations in prostate cancer, DNA 
methylation alterations are the best characterized, an  are, therefore, the most mature for 
translation to biomarkers for prostate cancer screening/diagnosis, risk stratification, and 
treatment/disease monitoring.  
 
CONCLUSION 
Prostate cancer progression, neuroendocrine transdifferentiation, and treatment responses are 
all regulated by epigenetics. A genomic landscape study has identified aberrant epigenetic events 
in CRPC and NEPC development. Although many genetic modulators involving the 
development and maintenance of advanced prostate canc rs have been under preclinical and 
clinical investigation, recent data reveal that many of the signaling pathways are also 
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epigenetically dysregulated in advanced prostate cancers including those involved in cell to cell 
adhesion, development of epithelial–mesenchymal transition, and the regulation and 
maintenance of stem cells. Therefore, epigenetic targe ing may represent an alternative 
therapeutic regimen to treatment with genetic modulator inhibitors. More studies are warranted 
to gain better understanding of the role of epigenetics in the development of advanced prostate 
cancers and crosstalk with lineage plasticity of NEPC progression. Moreover, advanced prostate 
cancers have complex molecular expression and epigenetic patterns, leading to inconsistent 
results when using a single class of drugs. Ongoing preclinical and clinical trials have shed light 








• Patients who receive anti-androgen treatments are mo likely to develop castration 
resistant prostate cancer. 
• A genomic landscape study has identified aberrant epigenetic events in CRPC and NEPC 
development. 
• Epigenetic targeting may represent an alternative therapeutic regimen for advanced 
prostate cancer. 
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Figure 1. This model depicts the molecular and phenotypic events associated with progression 
to castration-resistant prostate cancer (CRPC) and neuroendocrine prostate cancer (NEPC) and 
indicates both genomic and epigenetic modulators involving the lineage plasticity of prostate 
cancer. Genomic modulators include cooperative loss of RB1 and TP53; N-MYC and AURKA 
amplification; SRRM4 overexpression; FOXA1 loss and FOXA2 gain; Hypoxia-mediated 
signaling; elevated HP1α expression as well as PKC-lambda/iota reduction and serine synthesis. 
Epigenetic/reprogramming modulators include EZH2, EED, polycomb group proteins, SOX2, 
REST, and DEK1. ADT: Androgen deprivation therapy. 
 
Figure 2. Graphic summary of epigenetic regulation in prostate cancer and potential 
therapeutic options. Chromatin structure and accessibility to transcriptional factors are regulated 
dynamically by epigenetic mechanisms. Writers such as DNA methyltransferase (DNMT), 
histone lysine acetyltransferase (HAT), and histone lysine methyltransferase (KMT) catalyze the 
addition of epigenetic marks onto either DNA or histone tails. Readers such as BRD4 recognize 
a specific epigenetic mark. Erasers such as histone deacetylases (HDAC) and histone lysine 
demethylases (KDM) remove epigenetic marks. EZH2, EED, and SUZ12 are components 
of PRC2. The targets shown here are either approved r under clinical trials (ME: Methyl; AC: 
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